Feeling the Pulse in China

by swisscham in Engineering, Manufacturing

Healthcare and pharmaceutical firms across Europe are strengthening their presence in China, driven by the country’s high demand for medicine and the improving environment for research and development. Many European companies are drawn to China by the country’s R&D environment and focusing on local partners to make it easier to register in the market and gain approval for their research activities. The Swiss pharmaceutical giant Novartis opened an R&D center in Shanghai in 2007. Two years later, it invested another USD 1 billion (EUR 760 million) to add 1,000 researchers, making the center the third largest R&D base for Novartis behind their centers in Switzerland and the US. In 2011, Novartis acquired an 85% stake in Zhejiang-based Tianyuan Bio-Pharmaceutical Co Ltd, in a deal that significantly increased Novartis’ share in China’s vaccine market.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Your Swiss Business Platform in China

SwissCham China has roughly 600 company members. Our Chamber maintains a strong relationship with the Embassy of Switzerland, Switzerland Global Enterprise, Swissnex and Switzerland Tourism. As the representative of the Swiss companies established in China, our goal is to help you to increase your business and visibility, especially amongst the Sino-Swiss business community.

Become A Member

Sign Up For Our Newsletter

  • This field is for validation purposes and should be left unchanged.
July 28, 2022
Published By nestle.com in Hospitality / Tourism / Retail
July 27, 2022
Published By reuters.com in Bank / Finance / Insurance
July 13, 2022
Published By swissinfo.ch in Legal / Tax / Consulting / Services
July 13, 2022
Published By mumnet.com in Hospitality / Tourism / Retail